Next Article in Journal
Thymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
Next Article in Special Issue
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Previous Article in Journal
Bulked Segregant Analysis Coupled with Whole-Genome Sequencing (BSA-Seq) Mapping Identifies a Novel pi21 Haplotype Conferring Basal Resistance to Rice Blast Disease
Previous Article in Special Issue
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 6
10.3390/ijms21062164
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

by
Takahiro Ozutsumi
,
Tadashi Namisaki
*,
Naotaka Shimozato
,
Kosuke Kaji
,
Yuki Tsuji
,
Daisuke Kaya
,
Yukihisa Fujinaga
,
Masanori Furukawa
,
Keisuke Nakanishi
,
Shinya Sato
,
Yasuhiko Sawada
,
Soichiro Saikawa
,
Koh Kitagawa
,
Hiroaki Takaya
,
Hideto Kawaratani
,
Mitsuteru Kitade
,
Kei Moriya
,
Ryuichi Noguchi
,
Takemi Akahane
,
Akira Mitoro
and
Hitoshi Yoshiji
add Show full author list remove Hide full author list
Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2164; https://doi.org/10.3390/ijms21062164
Submission received: 11 February 2020 / Revised: 19 March 2020 / Accepted: 19 March 2020 / Published: 21 March 2020
(This article belongs to the Special Issue Diabetic Liver Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:
Hepatocellular carcinoma (HCC) is the strongest independent predictor of mortality in non-alcoholic steatohepatitis (NASH)-related cirrhosis. The effects and mechanisms of combination of sodium-dependent glucose cotransporter inhibitor and canagliflozin (CA) and dipeptidyl peptidase-4 inhibitor and teneligliptin (TE) on non-diabetic NASH progression were examined. CA and TE suppressed choline-deficient, L-amino acid-defined diet-induced hepatic fibrogenesis and carcinogenesis. CA alone or with TE significantly decreased proinflammatory cytokine expression. CA and TE significantly attenuated hepatic lipid peroxidation. In vitro studies showed that TE alone or with CA inhibited cell proliferation and TGF-β1 and α1 (I)-procollagen mRNA expression in Ac-HSCs. CA+TE inhibited liver fibrogenesis by attenuating hepatic lipid peroxidation and inflammation and by inhibiting Ac-HSC proliferation with concomitant attenuation of hepatic lipid peroxidation. Moreover, CA+TE suppressed in vivo angiogenesis and oxidative DNA damage. CA or CA+TE inhibited HCC cells and human umbilical vein endothelial cell (HUVEC) proliferation. CA+TE suppressed vascular endothelial growth factor expression and promoted increased E-cadherin expression in HUVECs. CA+TE potentially exerts synergistic effects on hepatocarcinogenesis prevention by suppressing HCC cell proliferation and angiogenesis and concomitantly reducing oxidative stress and by inhibiting angiogenesis with attenuation of oxidative stress. CA+TE showed chemopreventive effects on NASH progression compared with single agent in non-diabetic rat model of NASH, concurrent with Ac-HSC and HCC cell proliferation, angiogenesis oxidative stress, and inflammation. Both agents are widely, safely used in clinical practice; combined treatment may represent a potential strategy against NASH.

Graphical Abstract

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) includes the entire spectrum of fatty liver disease, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), significant liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). We have shown that blockade of angiotensin-II (AT-II) signaling at the AT-II type-1 receptor served to inhibit hepatic fibrogenesis together with the suppression of hepatic stellate cell (Ac-HSC) activation [1]. Blockade of the renin-angiotensin system with clinically relevant doses of angiotensin (AT)1R blocker (ARB: losartan) was found to inhibit both hepatocarcinogenesis [2] and progression of HCC [3] while at the same time inhibiting vascular endothelial growth factor (VEGF)-mediated neovascularization. It is important to recognize that the relationship between activated HSCs and the pathogenesis of NASH has been considered with respect to the multiple parallel hits hypothesis, and includes factors such as endotoxin and oxidative stress that are currently perceived as key contributors to the progression from fatty liver to NASH [4]. We have also recently shown that administration of fructose resulted in an increase in the extent of transport of endogenous gut-derived bacterial endotoxin by the portal vein; this leads to liver fibrosis and hepatocarcinogenesis via induction of lipopolysaccharide (LPS)/Toll-like receptor 4 signaling in a choline-deficient, l-amino-acid-defined (CDAA)-fed rat model [5]. Miura et al. have shown that proinflammatory cytokines and receptors including the C-C motif chemokine receptor 2 (CCR2), tumor necrosis factor-α (TNFα) and interleukin 6 (IL-6) derived from Kupffer cells all contribute to the progression of NASH and to the development of HCC in the CDAA diet-induced NASH model [6,7,8,9].
NASH is frequently accompanied by metabolic disorders such as type 2 diabetes mellitus (T2DM) [10]. We previously reported that the SGLT2-I, ipragliflozin, successfully ameliorates liver fibrosis in diabetic rats by improving insulin sensitivity [11]. The anti-cancer effects of canagliflozin (CA) have been attributed to inhibition of mitochondrial complex I and mitochondrial respiration [12]. Furthermore, SGLT2 is functionally expressed in various cancers including pancreatic, prostate [13], liver [14], and colon cancers [15], and SGLT2 inhibitors (SGLT2-Is) exhibit antitumor effects on these cancers [16]. We have recently shown that SGLT2 inhibitors may function as novel anti-cancer agents by inhibiting angiogenesis and progression to HCC in a mouse xenograft mouse model [17]. Dipeptidyl peptidase-4 inhibitors (DPP4-Is) are commonly prescribed for the treatment of T2DM. Two randomized controlled trials recently showed that use of the DPP4-I, sitagliptin, alone does not significantly attenuate liver fibrosis and liver fat in patients with NAFLD [18,19]. DPP4 has been identified as a multifunctional glycoprotein involved in different biological processes, including inflammation, liver fibrosis, malignant transformation, and tumor immunity [20,21]. It is highly expressed in the liver, especially in the endothelial cells (ECs), and its expression is increased in HCC [22]. While we observed that sitagliptin monotherapy exerted significant inhibitory effects on liver fibrogenesis and carcinogenesis in a rat model of steatohepatitis [23], it may be difficult to completely suppress the cumulative development of liver fibrosis and HCC using a single agent in clinical practice [2,24]. Our previous study has shown that the combined use of sitagliptin and either losartan or obeticholic acid showed a synergistic repressive effect on NASH development in experimental models [22,25]. Japan has just recently approved the use of a fixed-dose combined tablet of teneligliptin (20 mg) and canagliflozin (100 mg). As such, the impact of clinically equivalent doses of CA (100 mg/day) and teneligliptin (TE) (20 mg/day) [26] and their impact on the progression of NASH progression was the focus of this study. Furthermore, the combined use of empagliflozin (SGLT2-I) and linagliptin (DPP4-I) exhibited antifibrotic effects accompanied by antisteatotic and anti-inflammatory effects in diabetic mice [27]. The present study examined the effects of CA and TE on hepatic fibrogenesis and carcinogenesis, as well as the potential underlying mechanisms in a rat model of NASH.

2. Results

2.1. General Findings

The baseline characteristics of the six-week-old F344 rats are showed in Table 1. The final body weights of the choline-sufficient, L-amino acid-defined (CSAA)-fed rats (G1) were greater than those that of the CDAA-fed rats (G2–G5). The relative liver weights of the G2–G5 rats were greater than those of the G1 rats. Serum alanine aminotransferase (ALT) levels were significantly augmented in the G2–G5 rats compared with the G1 rats and were significantly lower in G3 and G5 compared with G2. There were no significant differences in serum concentrations of albumin, total bilirubin, and triglyceride among the groups. Plasma glucagon, serum glucose, and insulin levels, and the quantitative insulin sensitivity check index were not significantly altered in G3 or G4 rats. Similarly, no significant differences in hepatic glucagon-like peptide-1 (GLP-1) mRNA expression levels were observed among the experimental groups (data not shown).

2.2. Effects of Canagliflozin (CA) and Teneligliptin (TE) on Hepatic Fibrogenesis

Extensive collagen deposition in liver was observed in the G2 rats. Hepatic fibrogenesis was significantly reduced in G3 and G4 compared with that of G2 rats. CA+TE (G5) showed a more potent inhibitory effect than either monotherapy (Figure 1). No fibrosis development was observed in G1. Immunohistochemistry analysis revealed a significantly reduced number of α-smooth muscle actin (SMA)-positive Ac-HSCs after treatment with CA and TE (Figure 2a). A significant decrease in α-SMA-positive Ac-HSC numbers was observed following treatment with CA and TE. Computer-assisted semiquantitative analysis of α-SMA immunohistochemistry revealed a decrease in the α-SMA staining area as well as suppression of hepatic fibrogenesis (Figure 2b). CA and TE treatment significantly inhibited hepatic mRNA expression of transforming growth factor (TGF-β1) and α1(I)-procollagen compared with that in the CDAA diet group (G2; Figure 3a,b). Similar to the effect on liver fibrosis, CA+TE showed more potent inhibitory effects on hepatic expression of TGF-β1 and α1(I)-procollagen than did the effects of either single agent. The inhibitory effects of CA and TE were of a comparable magnitude to the observed effects on liver fibrosis.

2.3. In vitro Effects of CA and TE on Ac-HSCs

No significant microscopic morphologic changes were observed in HSCs among the five groups during the experimental period. Treatment with TE, either alone or combined with CA, significantly attenuated Ac-HSC proliferation (Figure 4a) as well as TGF-β1 (Figure 4b) and α1(I)-procollagen (Figure 4c) mRNA expression. On the other hand, treatment with CA alone showed no significant effect on either Ac-HSC proliferation or TGF-β1 and α1(I)-procollagen mRNA expression.
(A) Ac-HSC proliferation was attenuated by single treatment using CA and TE, whereas CA+TE showed a stronger suppressive effect compared with both monotherapies. CA and TE (G5) showed significantly stronger inhibition of TGF-β1 (B) and α1(I)-procollagen (C) mRNA expression in Ac-HSC compared with the single treatment groups (G3, G4). These inhibitory effects closely matched the changes observed in Ac-HSC proliferation.

2.4. Effects of CA and TE on Hepatic Inflammatory Cytokine Levels

Levels of TNF-α, IL-6, and CCL2 in the liver significantly increased in G2 rats (fed a CDAA diet) compared with those in G1. However, the CDAA diet-induced-increases in these three parameters were significantly decreased in G3 and G5 (treated with CA and CA + TE, respectively), whereas treatment with TE alone did not significantly influence these parameters (Figure 5).
Levels of hepatic (A) TNF-α, (B) IL-6, and (C) CCL2 were significantly increased in the choline-deficient, L-amino acid-defined (CDAA) diet group (G2) compared with the CSAA diet group (G1). The CDAA diet-induced increase in these three parameters was significantly decreased in CA-treated (G3) and CA + TE (G5) groups. However, no significant reduction was observed in these parameters in TE-treated group (G4). Values represent mean ± SD (n = 10). *p < 0.05, ** p < 0.01.

2.5. Effects of CA and TE on Preneoplastic Lesion Development

The effects of CA and TE on placental glutathione S-transferase (GST-P)-positive preneoplastic lesions in conjunction with neovascularization were examined. The livers of rats on the CDAA diet for 16 weeks exhibit features of fatty cirrhosis, including numerous and various sized neoplastic nodules with aberrant histologic, architectural, and cytoplasmic features together with nuclear atypia (Figure 6a,b). Semiquantitative analysis showed a significant decrease in both GST-P-positive preneoplastic lesion size and number in G2 rats compared with those in G1. Similar to the effects on liver fibrogenesis, combined treatment with CA and TE showed stronger inhibitory effects compared with use of either single agent (Figure 6c). No GST-P-positive lesions were observed in G1 rats. CA+TE exerted more potent suppressive effects on hepatic CD31 and VEGF mRNA expression compared with use of either single agent (Figure 7a,b). These effects closely matched the suppression of GST-P-positive preneoplastic lesions.

2.6. Effects of CA and TE on Hepatocellular Carcinoma (HCC) Cells and Endothelial Cells (ECs) in vitro

Treatment using CA alone or in combination with TE significantly inhibited proliferation of two human HCC cell lines (HepG2 and Huh7) (Figure 8a,b) and ECs (Figure 8c). However, TE showed no significant effect on the proliferation of these three cell types. We performed a more extensive examination of the in vitro effects of CA and TE on the expression of E-cadherin and VEGF in primary human umbilical vein endothelial cell (HUVEC) culture. CA and TE, each acting alone, promoted increased expression of the epithelial marker, E-cadherin, and at the same time suppressed the expression of the angiogenesis marker, VEGF, in HUVEC culture (Figure 8d,e). Simultaneous administration of both agents resulted in more potent stimulatory and inibitory effects on E-cadherin and VEGF expression, respectively, than detected in response to either agent alone.

2.7. Effects of CA and TE on Hepatic Oxidative Stress

Reactive oxygen species (ROS) contribute to NASH progression; therefore, we examined the effects of CA and TE on markers of lipid peroxidation and oxidative DNA damage, particularly MDA and 8-OHdG, respectively. Rats fed a CDAA diet showed elevated levels of malondialdehyde (MDA) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in the liver (Figure 9a,b), and these levels were significantly decreased in G3 and G4 compared with G2. The suppressive effects of CA and TE on MDA and 8-OHdG were almost equivalent, and CA+TE exerted a more potent inhibitory effect than either single agent.

2.8. Changes in the Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score

Microscopic examination revealed significant reductions in steatosis, lobular inflammation and hepatocellular ballooning in groups G3 and G5 (Figure 10 and Table 2) (i.e., those treated with CA and CA + TE, respectively) compared to what was observed among the G2 rats (fed a CDAA diet). These changes were accompanied by a significant decrease in the alanine aminotransferase (ALT) level, indicating that CA, but not TE, had both cytoprotective and anti-inflammatory effects on target hepatocytes.

2.9. Measurement of Serum TE Concentration

Serum TE concentration was 1.73 ± 0.27 and 1.88 ± 0.31 nmol/L in G4 and G5, respectively, which were higher than the IC50 value of TE (1.14 nmol/L).

2.10. Effects of CA and TE on DPP4 Activity

DPP4 activity was significantly augmented in G2 compared with in G1 and was significantly suppressed in G4 and G5 compared with G2 (Figure 11).

3. Discussion

The present study found that CA and TE markedly attenuated CDAA diet-induced hepatic fibrogenesis and carcinogenesis. CA+TE showed greater antifibrotic and anticarcinogenic effects than monotherapy. These inhibitory effects were concurrent with the inhibition of Ac-HSC and HCC cell proliferation, VEGF-mediated neovascularization, ROS, and inflammation. Although monotherapy is preferred [23], complete inhibition of the cumulative development of liver fibrosis and carcinogenesis using a single pharmocotherapeutic agent may be challenging in experiments [24,28,29] and in clinical practice [30]. Therefore, CA and TE may be used as therapeutic agents to target fibrosis in patients with NASH. The substantial therapeutic benefits of CA and TE in slowing NASH progression need to be confirmed for future clinical applications.
CA and TE were effective against liver fibrosis via different action mechanisms, including inhibition of Ac-HSC proliferation, hepatic lipid peroxidation, and inflammation. CA suppressed the activation of protein kinase C [31,32], the NADPH oxidase system, and subsequent ROS production [33,34] in various vascular cells [35]. In addition, we demonstrated that CA potentially inhibits lipid peroxidation in NASH progression. It contributes to inflammatory and fibrotic changes in diabetic kidney disease [36]. Studies investigating the effects of SGLT2-I on chronic inflammation in neural tissues and skeletal muscles have demonstrated that a decrease in the expression of proinflammatory cytokine levels and macrophage accumulation [37] mechanistically underlies the pharmacological activities of canagliflozin. We have previously shown that DPP4, but not SGLT2, expressed by Ac-HSCs and sitagliptin (a DPP4-I) inhibits hepatic fibrosis via the suppression of Ac-HSCs in rats [21]. Increasing evidence from in vitro and in vivo studies suggests that the inhibition of DPP4 attenuates oxidative stress [38,39]. These findings support our theory that CA+TE inhibits liver fibrogenesis by attenuating hepatic lipid peroxidation and inflammation and by inhibiting Ac-HSC proliferation with concomitant attenuation of hepatic lipid peroxidation, respectively.
Consistent with our previous findings [17], CA-mediated inhibition of cell proliferation correlated with G2/M phase arrest and was followed by human HCC cell apoptosis [40]. The concentration of CA (10 µM) used in the present study corresponds to the serum concentrations achieved using clinical doses [41]. CA was shown to promote apoptosis of human HCC cells by enhancing cleavage of caspase [40]. Moreover, the proliferative action of CA occurs in the absence of cell death and is due, in part, to blockade of cyclin A expression inhibition [42]. Conversely, in vitro studies have demonstrated that CA (100 µM) interferes with the anti-proliferative effects on non-small lung cancer cell, indicating that high doses of SGLT2 may inhibit HCC cell proliferation due to cytotoxicity [43]. In contrast, 1–50 µM tofogliflozin (another SGLT2-I) did not modulate the proliferation of SGLT2-expressing human HCC cells [44]. These findings warrant further investigation and future studies should consider the role of different SGLT2-Is to investigate the physiological mechanisms and strategies that protect against NASH progression. These findings suggest that the anti-cancer activity of SGLT2-Is may be at least partially explained by the direct anti-cancer effects of SGLT2-I on HCC cells.
However, the exact mechanisms underlying the effects of CA and TE remain to be elucidated. We recently showed that the inhibitory effects of clinically equivalent doses of DPP4-I on hepatocarcinogenesis were mainly mediated via EC tube formation and oxidative DNA damage and were not due to the direct action of in vitro EC or HCC cell proliferation [22]. The drug, sitagliptin, has recently been shown to have inhibitory effects on NASH-related progression to HCC via its inhibitory actions at the p62/Keap1/Nrf2-pentose phosphate pathway [45]. Furthermore, the dipeptidyl peptidase (DPP)-4 inhibitor, KR62436, promoted primary tumor growth, and lung metastasis via induction of the CXCL12/CXCR4/mTOR/EMT signaling axis in a syngeneic mouse model [46]. The differences in antitumor effects of DPP4 inhibitors might be explained at least in part by differences in pharmacological activities [26]. Conversely, CA was shown to inhibit EC proliferation in a concentration-dependent manner [42]. This suggests that inhibition of both CA and TE synergistically reduces neovascularization. We are currently investigating the direct interaction between CA and TE, angiogenesis, cell proliferation, and ROS during hepatocarcinogenesis. Nevertheless, the present findings indicate that CA and TE potentially exert synergistic effects on the prevention of hepatocarcinogenesis by suppressing HCC proliferation and angiogenesis and concomitantly reducing the oxidative stress and by inhibiting angiogenesis with attenuation of oxidative stress, respectively.
The present study employed a CDAA model to examine the effects of CA and TE on hepatic fibrogenesis and carcinogenesis. The CDAA diet-induced histological changes similar to those observed in human NASH [47]. However, the CDAA dietary model of NASH does not display insulin resistance, obesity, and impaired glucose tolerance, which are clinical characteristics of NASH in humans. The antifibrotic effects of TE were not correlated with local GLP-1 expression in CDAA-induced NASH. The therapeutic impact under conditions of insulin resistance requires further investigation to accurately evaluate the pharmacological effects of drugs.
Collectively, studies have shown that CA and TE have synergistic effects on hepatic fibrogenesis and carcinogenesis with concurrent suppression of HSC and HCC proliferation, angiogenesis, oxidative stress, and inflammation. Furthermore, the inhibitory effects of both agents on NASH progression may be achieved at clinically comparable doses in non-diabetic rats. CA+TE could be more effective in suppressing hepatic fibrosis progression and further preventing fibrosis-associated HCC development in patients with NASH, who are at an increased risk of developing cirrhosis and HCC.

4. Materials and Methods

4.1. Animals and Reagents

A total of 50 six-week-old male Fischer 344 (F344) rats (CLEA Japan Inc., Tokyo, Japan) were housed in stainless steel mesh cages under the following controlled conditions: temperature, 23 °C ± 3 °C; relative humidity, 50% ± 20%; 10–15 air/h; and 12-h day/night cycle. Animals had ad libitum access to tap water. CA and TE were kindly provided from Mitsubishi Tanabe Pharma Co. Ltd. (Osaka, Japan). Conventional chemical reagents were purchased from Nacalai Tesque (Kyoto, Japan). CDAA and CSAA diets were purchased from CLEA Japan Inc. (Tokyo, Japan).

4.2. Animal Treatment

All experiments were performed over a 16-week period. Rats were randomly assigned to five groups: groups 1 to 5 (G1–G5; n = 10 per group). Rats in G1 were designated as the negative control group and were fed a CSAA diet, whereas rats in G2–G5 were fed a CDAA diet. Rats in G1 and G2 were administered phosphate-buffered saline via oral gavage once daily during the experimental period. Rats in G3 and G4 were administered clinically equivalent doses of CA (10 mg/kg/day) [17] and TE (0.3 mg/kg/day) [48], respectively, via daily oral gavage. Rats in G5 were treated with a combination of CA and TE. No adverse effects were observed in the present study. There were no differences in food intake among the groups. At end of the study period, rats were anesthetized using isoflurane, and various indices were measured. Serum TE concentration was determined by liquid chromatography–tandem mass spectrometry [49,50]. Analysis was performed using the LCMS-8060 triple quadrupole mass spectrometer with the Nexera UHPLC system (Shimadzu Corporation, Kyoto, Japan) [51]. Serum DPP4 activity was measured using a DPP4 activity assay kit (Biovision, Milpitas, CA, USA) [52]. All procedures were performed according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86–23, revised 1985). All experiments were approved by the Animal Care and Use Committee of Nara Medical University.

4.3. Quantitative Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis

RNA was extracted from powdered frozen liver tissue using the RNeasy Mini Kit (QIAGEN, Tokyo, Japan) and complementary DNA (cDNA) was synthesized from RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems Inc., Foster City, CA, USA), according to the manufacturer’s instructions. Expression levels of mRNA for TGF-β1 and α1(I)-procollagen were measured in liver tissue and isolated activated hepatic stellate cell (Ac-HSCs), and CD31 and VEGF mRNA was measured in liver tissue and E-cadherin and VEGF mRNA was measured in HUVECs and quantified by RT-PCR using SYBR Green on a Step One Plus sequence-detection system (Applied Biosystems Inc.). PCR was conducted as follows: samples were heated for 20 s at 95 °C followed by 40 cycles of denaturing for 3 s at 95 °C and annealing for 30 s at 60 °C. Glyceraldehyde 3-phosphate dehydrogenase (GAPHD) was used as an endogenous control. The following primer sequences used: TGF-β1, forward 5′-CGGCAGCTGTACATTGACTT-3′ and reverse 5′-AGCGCACGATCATGTTGGAC-3′; α1(I)-procollagen, forward 5′-AGCTCCTGGGCCTATCTGATGA-3′; CD31, forward, 5′-GGCGTCCTGTCCGGAATC-3′ and reverse 5′-AGAACTCCTGCACAGTGACGTATT-3′; VEGF, forward, 5′-CCATGAACTTTCTGCTGTCTT-3′ and reverse 5′-CCATGAACTTTCTGCTGTCTT-3′; E-cadherin forward, 5′-TCCATTTCTTGGTCTACGCC-3′ and reverse 5′-CACCTTCAGCCA ACCTGTTT-3′ and GAPHD, forward 5′-TGGCAAATTCCATGGCA-3′ and reverse 5′-CCTTCTCCATGGTGGT-3′.

4.4. Histological and Immunohistochemical Analyses

Liver samples from the five groups were routinely processed to create 5-μm-thick sections of formalin-fixed paraffin-embedded (FFPE) sections for Sirius red staining to evaluate hepatic fibrosis. Immunohistochemistry for α-SMA (DAKO, Kyoto, Japan) and enzyme-altered preneoplastic lesions (GST-P) (MBL Co. Ltd., Nagoya, Japan) was conducted as previously described [53,54]. FFPE tissue sections were semiquantified using ImageJ (National Institutes of Health). Ten microscopic visual fields (×40 magnification) were analyzed per specimen in each group (n = 10) using ImageJ analysis, as previously described [55].

4.5. Protein Expression Analysis

After determining the protein concentration of 200-mg frozen liver samples, levels of TNF-α (Biosource International, Camarillo, CA), IL-6 (Quantikine HS; R&D Systems, Minneapolis, MN), CCL2 (LifeSpan Biosciences, Seattle, WA, USA), malondialdehyde (MDA, NWLSS, Vancouver, WA, USA), and 8-hydroxydeoxyguanosine (8-OHdG, AbCam, Cambridge, UK) were determined using enzyme-linked immunosorbent assay kits according to the manufacturer’s instructions.

4.6. In Vitro Assays

Frozen liver tissue samples were digested in vitro using pre-warmed pronase and collagenase solution. Freshly isolated HSCs from F344 rats were plated at a density of 5 × 105 cells/mL on uncoated plastic dishes [47]. After culture for 5 days, the HSCs showed myofibroblast-like characteristics with reduced lipid vesicles and increased expression of α-SMA. After activation of HSCs by culture on plastic plates for 7 days, all cells were distributed homogeneously and were all α-SMA-positive. HepG2 and Huh7 human liver cancer cells and HUVECs were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). The in vitro effects of CA and TE on the cell proliferation were assessed using a colorimetric assay (Roche Applied Science, Laval, Canada) according to the cleavage of the tetrazolium salt, WST-1, by mitochondrial dehydrogenases to form formazan in viable cells (Roche Applied Science, Laval, Canada). Briefly, Ac-HSCs, HepG2 cells, Huh7 cells, or HUVECs were seeded in 96-well plates with 100 μL of fetal bovine serum-free media. After 48 h incubation, 20 μL of WST-1 reagent (Sigma Aldrich, Poole, UK) was added and plates were incubated for 1 h. Absorbance was measured at 450 nm using a reference wavelength of 620 nm within 30 min using a plate reader.

4.7. Statistical Analysis

Data are presented as mean ± standard deviation. One-way analysis of variance followed by Bonferroni or Tukey’s post hoc tests (in vitro study) was performed. All statistical analyses were performed using IBM Statistical Package for the Social Sciences software version 22. All tests were two-tailed and p-values of <0.05 were considered significant.

Author Contributions

Conceptualization, H.Y.; methodology, K.K. (Kousuke Kaji); validation, S.S. (Soichiro Saikawa), and S.S. (Shinya Sato); investigation, Y.S., and A.M.; resources, H.T., N.S., Y.F., M.F., D.K., Y.T., and K.K. (Koh Kitagawa); data curation, K.N., H.K., K.M., T.A., R.N., and M.K. (Mitsuteru Kitade); writing—original draft preparation, T.O.; writing—review and editing, T.N. and H.Y. All authors have read and approved the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

CDAACholine-deficient, L-amino acid
CSAACholine-sufficient, L-amino acid-defined
ECEndothelial cell
FFPEFormalin-fixed paraffin-embedded
NAFLDNon-alcoholic fatty liver disease
NIHNational Institutes of Health
OLETFOtsuka Long-Evans Tokushima fatty
ROSReactive oxygen species
SDStandard deviation
VEGFVascular endothelial growth factor
CCR2C-C motif chemokine receptor 2
TNFαTumor necrosis factor-α
IL-6Interleukin 6

References

  1. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34, 745–750. [Google Scholar] [CrossRef] [PubMed]
  2. Yoshiji, H.; Noguchi, R.; Namisaki, T.; Moriya, K.; Kitade, M.; Aihara, Y.; Douhara, A.; Kawaratani, H.; Nishimura, N.; Fukui, H. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J. Gastroenterol. 2014, 49, 1421–1429. [Google Scholar] [CrossRef] [PubMed]
  3. Yoshiji, H.; Noguchi, R.; Ikenaka, Y.; Kaji, K.; Aihara, Y.; Fukui, H. Impact of renin-angiotensin system in hepatocellular carcinoma. Curr. Cancer Drug Targets 2011, 11, 431–441. [Google Scholar] [CrossRef] [PubMed]
  4. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836–1846. [Google Scholar] [CrossRef] [PubMed]
  5. Seki, K.; Kitade, M.; Nishimura, N.; Kaji, K.; Asada, K.; Namisaki, T.; Moriya, K.; Kawaratani, H.; Okura, Y.; Takaya, H.; et al. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. Oncotarget 2018, 9, 28638–28651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139, 323–334 e327. [Google Scholar] [CrossRef] [Green Version]
  7. Miura, K.; Yang, L.; van Rooijen, N.; Ohnishi, H.; Seki, E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest Liver Physiol. 2012, 302, G1310–G1321. [Google Scholar] [CrossRef] [Green Version]
  8. Miura, K.; Ishioka, M.; Minami, S.; Horie, Y.; Ohshima, S.; Goto, T.; Ohnishi, H. Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice. J. Biol. Chem. 2016, 291, 11504–11517. [Google Scholar] [CrossRef] [Green Version]
  9. Miura, K.; Yang, L.; van Rooijen, N.; Brenner, D.A.; Ohnishi, H.; Seki, E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013, 57, 577–589. [Google Scholar] [CrossRef] [Green Version]
  10. Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005, 42, 44–52. [Google Scholar] [CrossRef]
  11. Nishimura, N.; Kitade, M.; Noguchi, R.; Namisaki, T.; Moriya, K.; Takeda, K.; Okura, Y.; Aihara, Y.; Douhara, A.; Kawaratani, H.; et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J. Gastroenterol. 2016, 51, 1141–1149. [Google Scholar] [CrossRef] [PubMed]
  12. Villani, L.A.; Smith, B.K.; Marcinko, K.; Ford, R.J.; Broadfield, L.A.; Green, A.E.; Houde, V.P.; Muti, P.; Tsakiridis, T.; Steinberg, G.R. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol. Metab. 2016, 5, 1048–1056. [Google Scholar] [CrossRef] [PubMed]
  13. Scafoglio, C.R.; Villegas, B.; Abdelhady, G.; Bailey, S.T.; Liu, J.; Shirali, A.S.; Wallace, W.D.; Magyar, C.E.; Grogan, T.R.; Elashoff, D.; et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci. Transl. Med. 2018, 10. [Google Scholar] [CrossRef] [PubMed]
  14. Shiba, K.; Tsuchiya, K.; Komiya, C.; Miyachi, Y.; Mori, K.; Shimazu, N.; Yamaguchi, S.; Ogasawara, N.; Katoh, M.; Itoh, M.; et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 2018, 8, 2362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Scafoglio, C.; Hirayama, B.A.; Kepe, V.; Liu, J.; Ghezzi, C.; Satyamurthy, N.; Moatamed, N.A.; Huang, J.; Koepsell, H.; Barrio, J.R.; et al. Functional expression of sodium-glucose transporters in cancer. Proc. Natl. Acad. Sci. USA 2015, 112, E4111–E4119. [Google Scholar] [CrossRef] [Green Version]
  16. Komatsu, S.; Nomiyama, T.; Numata, T.; Kawanami, T.; Hamaguchi, Y.; Iwaya, C.; Horikawa, T.; Fujimura-Tanaka, Y.; Hamanoue, N.; Motonaga, R.; et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr. J. 2019. [Google Scholar] [CrossRef] [Green Version]
  17. Kaji, K.; Nishimura, N.; Seki, K.; Sato, S.; Saikawa, S.; Nakanishi, K.; Furukawa, M.; Kawaratani, H.; Kitade, M.; Moriya, K.; et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int. J. Cancer 2018, 142, 1712–1722. [Google Scholar] [CrossRef] [Green Version]
  18. Joy, T.R.; McKenzie, C.A.; Tirona, R.G.; Summers, K.; Seney, S.; Chakrabarti, S.; Malhotra, N.; Beaton, M.D. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J. Gastroenterol. 2017, 23, 141–150. [Google Scholar] [CrossRef]
  19. Cui, J.; Philo, L.; Nguyen, P.; Hofflich, H.; Hernandez, C.; Bettencourt, R.; Richards, L.; Salotti, J.; Bhatt, A.; Hooker, J.; et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J. Hepatol. 2016, 65, 369–376. [Google Scholar] [CrossRef] [Green Version]
  20. Kajiyama, H.; Kikkawa, F.; Maeda, O.; Suzuki, T.; Ino, K.; Mizutani, S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002, 63, 158–165. [Google Scholar] [CrossRef]
  21. Kaji, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Aihara, Y.; Douhara, A.; Moriya, K.; Kawaratani, H.; Shirai, Y.; Yoshii, J.; et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J. Gastroenterol. 2014, 49, 481–491. [Google Scholar] [CrossRef] [PubMed]
  22. Okura, Y.; Namisaki, T.; Moriya, K.; Kitade, M.; Takeda, K.; Kaji, K.; Noguchi, R.; Nishimura, N.; Seki, K.; Kawaratani, H.; et al. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. Hepatol. Res. 2017, 47, 1317–1328. [Google Scholar] [CrossRef] [PubMed]
  23. Kaji, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Aihara, Y.; Shirai, Y.; Douhara, A.; Fukui, H. Possible involvement of angiogenesis in chronic liver diseases: Interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr. Med. Chem. 2012, 19, 1889–1898. [Google Scholar] [CrossRef] [PubMed]
  24. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Shirai, Y.; Aihara, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest Liver Physiol. 2011, 300, G1094–G1104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Shimozato, N.; Namisaki, T.; Kaji, K.; Kitade, M.; Okura, Y.; Sato, S.; Moriya, K.; Seki, K.; Kawaratani, H.; Takaya, H.; et al. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. Hepatol. Res. 2019, 49, 1147–1161. [Google Scholar] [CrossRef]
  26. Ceriello, A.; De Nigris, V.; Iijima, H.; Matsui, T.; Gouda, M. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 2019, 79, 733–750. [Google Scholar] [CrossRef] [Green Version]
  27. Jojima, T.; Tomotsune, T.; Iijima, T.; Akimoto, K.; Suzuki, K.; Aso, Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol. Metab. Syndr. 2016, 8, 45. [Google Scholar] [CrossRef] [Green Version]
  28. Douhara, A.; Moriya, K.; Yoshiji, H.; Noguchi, R.; Namisaki, T.; Kitade, M.; Kaji, K.; Aihara, Y.; Nishimura, N.; Takeda, K.; et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol. Med. Rep. 2015, 11, 1693–1700. [Google Scholar] [CrossRef] [Green Version]
  29. Buko, V.U.; Lukivskaya, O.Y.; Zavodnik, L.V.; Sadovnichy, V.V.; Petushok, N.E.; Tauschel, N.D. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation. Ukr Biokhim. Zh 2002, 74, 88–92. [Google Scholar]
  30. Bjornsson, E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol. Dietol. 2008, 54, 7–18. [Google Scholar]
  31. Inoguchi, T.; Battan, R.; Handler, E.; Sportsman, J.R.; Heath, W.; King, G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA 1992, 89, 11059–11063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Koya, D.; King, G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47, 859–866. [Google Scholar] [CrossRef] [PubMed]
  33. Inoguchi, T.; Li, P.; Umeda, F.; Yu, H.Y.; Kakimoto, M.; Imamura, M.; Aoki, T.; Etoh, T.; Hashimoto, T.; Naruse, M.; et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49, 1939–1945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Inoguchi, T.; Sonta, T.; Tsubouchi, H.; Etoh, T.; Kakimoto, M.; Sonoda, N.; Sato, N.; Sekiguchi, N.; Kobayashi, K.; Sumimoto, H.; et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: Role of vascular NAD(P)H oxidase. J. Am. Soc. Nephrol. 2003, 14, S227–S232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Maki, T.; Maeno, S.; Maeda, Y.; Yamato, M.; Sonoda, N.; Ogawa, Y.; Wakisaka, M.; Inoguchi, T. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. Sci. Rep. 2019, 9, 4703. [Google Scholar] [CrossRef]
  36. Heerspink, H.J.L.; Perco, P.; Mulder, S.; Leierer, J.; Hansen, M.K.; Heinzel, A.; Mayer, G. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019, 62, 1154–1166. [Google Scholar] [CrossRef] [Green Version]
  37. Naznin, F.; Sakoda, H.; Okada, T.; Tsubouchi, H.; Waise, T.M.; Arakawa, K.; Nakazato, M. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 2017, 794, 37–44. [Google Scholar] [CrossRef]
  38. Jo, C.H.; Kim, S.; Park, J.S.; Kim, G.H. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy. Kidney Blood Press Res. 2018, 43, 987–999. [Google Scholar] [CrossRef]
  39. Ku, H.C.; Chen, W.P.; Su, M.J. DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes. PLoS ONE 2013, 8, e54518. [Google Scholar] [CrossRef]
  40. Jojima, T.; Wakamatsu, S.; Kase, M.; Iijima, T.; Maejima, Y.; Shimomura, K.; Kogai, T.; Tomaru, T.; Usui, I.; Aso, Y. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2019, 20, 5237. [Google Scholar] [CrossRef] [Green Version]
  41. Liang, Y.; Arakawa, K.; Ueta, K.; Matsushita, Y.; Kuriyama, C.; Martin, T.; Du, F.; Liu, Y.; Xu, J.; Conway, B.; et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012, 7, e30555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Behnammanesh, G.; Durante, Z.E.; Peyton, K.J.; Martinez-Lemus, L.A.; Brown, S.M.; Bender, S.B.; Durante, W. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation. Front. Pharmacol. 2019, 10, 362. [Google Scholar] [CrossRef] [PubMed]
  43. Li, H.; Tong, C.W.; Leung, Y.; Wong, M.H.; To, K.K.; Leung, K.S. Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Front. Oncol. 2017, 7, 288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Obara, K.; Shirakami, Y.; Maruta, A.; Ideta, T.; Miyazaki, T.; Kochi, T.; Sakai, H.; Tanaka, T.; Seishima, M.; Shimizu, M. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget 2017, 8, 58353–58363. [Google Scholar] [CrossRef]
  45. Kawaguchi, T.; Nakano, D.; Koga, H.; Torimura, T. Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model. Liver Cancer 2019, 8, 359–372. [Google Scholar] [CrossRef]
  46. Yang, F.; Takagaki, Y.; Yoshitomi, Y.; Ikeda, T.; Li, J.; Kitada, M.; Kumagai, A.; Kawakita, E.; Shi, S.; Kanasaki, K.; et al. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis. Cancer. Res. 2019, 79, 735–746. [Google Scholar] [CrossRef] [Green Version]
  47. Aihara, Y.; Yoshiji, H.; Noguchi, R.; Kaji, K.; Namisaki, T.; Shirai, Y.; Douhara, A.; Moriya, K.; Kawaratani, H.; Fukui, H. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol. Res. 2013, 43, 1241–1250. [Google Scholar] [CrossRef]
  48. Yamamoto, M.; Ishizu, T.; Seo, Y.; Suto, Y.; Sai, S.; Xu, D.; Murakoshi, N.; Kimura, T.; Kawakami, Y.; Aonuma, K. Teneligliptin Prevents Cardiomyocyte Hypertrophy, Fibrosis, and Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats. J. Card Fail. 2018, 24, 53–60. [Google Scholar] [CrossRef]
  49. Eto, T.; Inoue, S.; Kadowaki, T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 2012, 14, 1040–1046. [Google Scholar] [CrossRef]
  50. Kadowaki, T.; Kondo, K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2013, 15, 810–818. [Google Scholar] [CrossRef]
  51. Rush, M.D.; van Breemen, R.B. Role of ammonium in the ionization of phosphatidylcholines during electrospray mass spectrometry. Rapid. Commun. Mass Spectrom. 2017, 31, 264–268. [Google Scholar] [CrossRef] [PubMed]
  52. Kim, S.J.; Kwon, S.K.; Kim, H.Y.; Kim, S.M.; Bae, J.W.; Choi, J.K. DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction. BMC Nephrol. 2019, 20, 75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Kaji, K.; Yoshiji, H.; Kitade, M.; Ikenaka, Y.; Noguchi, R.; Yoshii, J.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Moriya, K.; et al. Impact of insulin resistance on the progression of chronic liver diseases. Int. J. Mol. Med. 2008, 22, 801–808. [Google Scholar] [PubMed]
  54. Kitade, M.; Yoshiji, H.; Kojima, H.; Ikenaka, Y.; Noguchi, R.; Kaji, K.; Yoshii, J.; Yanase, K.; Namisaki, T.; Asada, K.; et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44, 983–991. [Google Scholar] [CrossRef]
  55. Namisaki, T.; Noguchi, R.; Moriya, K.; Kitade, M.; Aihara, Y.; Douhara, A.; Nishimura, N.; Takeda, K.; Okura, Y.; Kawaratani, H.; et al. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. 2016, 51, 162–172. [Google Scholar] [CrossRef]
Ijms 21 02164 g001 550
Figure 1. (a) Photomicrographs of liver sections stained with Sirius red. (b) Collagen content was calculated from Sirius red staining using image analysis software. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 1. (a) Photomicrographs of liver sections stained with Sirius red. (b) Collagen content was calculated from Sirius red staining using image analysis software. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g001
Ijms 21 02164 g002 550
Figure 2. (a) Immunohistochemical analysis of alpha-smooth muscle actin (α-SMA) expression. (b) α-SMA immunohistochemical staining is assessed using image analysis software. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 2. (a) Immunohistochemical analysis of alpha-smooth muscle actin (α-SMA) expression. (b) α-SMA immunohistochemical staining is assessed using image analysis software. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g002
Ijms 21 02164 g003 550
Figure 3. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic mRNA expression of TGF-β1 (a) and α1(I)-procollagen (b) in rats fed either the choline-sufficient, L-amino acid-defined (CSAA) diet (G1) or a choline-deficient, L-amino acid-defined (CDAA) diet (G2) and treated with CA (G3), TE (G4), or CA and TE (G5). Data represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 3. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic mRNA expression of TGF-β1 (a) and α1(I)-procollagen (b) in rats fed either the choline-sufficient, L-amino acid-defined (CSAA) diet (G1) or a choline-deficient, L-amino acid-defined (CDAA) diet (G2) and treated with CA (G3), TE (G4), or CA and TE (G5). Data represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g003
Ijms 21 02164 g004 550
Figure 4. Effects of canagliflozin (CA; 10 μM) and teneligliptin (TE; 5 μM) on cell proliferation (a) as well as mRNA expression of TGF-β1 (b) and α1 (I)-procollagen (c) in activated hepatic stellated cells. The in vitro effects of CA and TE on cell proliferation were assessed using a colorimetric assay. Values represent mean ± SD (n = 8). * p < 0.05. N.S.: No significance.
Figure 4. Effects of canagliflozin (CA; 10 μM) and teneligliptin (TE; 5 μM) on cell proliferation (a) as well as mRNA expression of TGF-β1 (b) and α1 (I)-procollagen (c) in activated hepatic stellated cells. The in vitro effects of CA and TE on cell proliferation were assessed using a colorimetric assay. Values represent mean ± SD (n = 8). * p < 0.05. N.S.: No significance.
Ijms 21 02164 g004
Ijms 21 02164 g005 550
Figure 5. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic inflammatory cytokines; (a) tumor necrosis factor-α (b) Interleukin-6 (c) C-C motif chemokine 2. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 5. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic inflammatory cytokines; (a) tumor necrosis factor-α (b) Interleukin-6 (c) C-C motif chemokine 2. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g005
Ijms 21 02164 g006 550
Figure 6. (a) Representative photomicrographs of GST-P-positive hepatic preneoplastic lesions. (b) Semiquantitative analysis of immunohistochemistry images using ImageJ. (c) Higher magnification GST-P-positive hepatic preneoplastic lesions (x100). G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA + canagliflozin (CA)); G4, Group 4 (CDAA + teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 6. (a) Representative photomicrographs of GST-P-positive hepatic preneoplastic lesions. (b) Semiquantitative analysis of immunohistochemistry images using ImageJ. (c) Higher magnification GST-P-positive hepatic preneoplastic lesions (x100). G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA + canagliflozin (CA)); G4, Group 4 (CDAA + teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g006
Ijms 21 02164 g007 550
Figure 7. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic (a) CD31 mRNA expression and (b) hepatic vascular endothelial growth factor (VEGF) protein expression. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 7. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic (a) CD31 mRNA expression and (b) hepatic vascular endothelial growth factor (VEGF) protein expression. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g007
Ijms 21 02164 g008 550
Figure 8. Effects of canagliflozin (CA; 10 μM) and teneligliptin (TE; 5 μM) on cell proliferation of (a) HepG2 cells and (b) Huh7 cells. Effects of both agents on (c) cell proliferation and (d) E-cadherin and (e) VEGF mRNA expression in human umbilical vein endothelial cells. Values represent mean ± SD (n = 8). * p < 0.05, ** p < 0.01. N.S.: No significance.
Figure 8. Effects of canagliflozin (CA; 10 μM) and teneligliptin (TE; 5 μM) on cell proliferation of (a) HepG2 cells and (b) Huh7 cells. Effects of both agents on (c) cell proliferation and (d) E-cadherin and (e) VEGF mRNA expression in human umbilical vein endothelial cells. Values represent mean ± SD (n = 8). * p < 0.05, ** p < 0.01. N.S.: No significance.
Ijms 21 02164 g008
Ijms 21 02164 g009 550
Figure 9. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic reactive oxygen species (ROS) production; (a) malondialdehyde (b) 8-hydroxy-2'-deoxyguanosine. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Figure 9. Effects of canagliflozin (CA) and teneligliptin (TE) on hepatic reactive oxygen species (ROS) production; (a) malondialdehyde (b) 8-hydroxy-2'-deoxyguanosine. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE); Values represent mean ± SD (n = 10). * p < 0.05, ** p < 0.01.
Ijms 21 02164 g009
Ijms 21 02164 g010 550
Figure 10. Representative images of hematoxylin–eosin-stained liver sections of different experimental groups (original magnification ×40). G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE).
Figure 10. Representative images of hematoxylin–eosin-stained liver sections of different experimental groups (original magnification ×40). G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA+CA+TE).
Ijms 21 02164 g010
Ijms 21 02164 g011 550
Figure 11. Effects of canagliflozin (CA) and teneligliptin (TE) on serum DPP4 activity. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE). Values represent mean ± SD (n = 10). * p < 0.05, N.S; not significant.
Figure 11. Effects of canagliflozin (CA) and teneligliptin (TE) on serum DPP4 activity. G1, Group 1 (choline-sufficient, L-amino acid-defined diet); G2, Group 2 (choline-deficient, L-amino acid-defined diet (CDAA)); G3, Group 3 (CDAA+ canagliflozin (CA)); G4, Group 4 (CDAA+ teneligliptin (TE)); G5, Group 5 (CDAA + CA + TE). Values represent mean ± SD (n = 10). * p < 0.05, N.S; not significant.
Ijms 21 02164 g011
Table
Table 1. Characteristics of the experimental groups in rats fed the CSAA-or CDAA diet.
Table 1. Characteristics of the experimental groups in rats fed the CSAA-or CDAA diet.
CSAACDAACDAA+CACDAA+TECDAA+CA+TE
(G1)(G2)(G3)(G4)(G5)
Number of rats1010101010
Body weight, g328.6 ± 15.7266.1 ± 11.8 ‡258.9 ± 9.6 ‡266.1 ± 14.2 ‡259.3 ± 12.3 ‡
Liver/ BW ratio, g/100gBW3.8 ± 0.15.2 ± 0.2 ‡5.4 ± 0.3 ‡5.1 ± 0.5 ‡5.2 ± 0.4 ‡
ALT, IU/L82.2 ± 8.6297.3 ± 31.0 ‡208.9 ± 13.0 ‡,†278.2 ± 33.1 ‡209.5 ± 29.2 ‡,†
ALB, g/dL3.9 ± 0.13.7 ± 0.13.8 ± 0.23.6 ± 0.33.8 ± 0.3
T-Bil, mg/dL0.13 ± 0.020.12 ± 0.030.11 ± 0.030.13 ± 0.020.11 ± 0.03
TG, mg/dL210.9 ± 39.1210.4 ± 18.4208.5 ± 23.2222.5 ± 37.5219.3 ± 18.9
Glucose, mg/dL161.2 ± 36.9158.4 ± 31.6138.1 ± 31.5136.8 ± 21.9143.4 ± 13.8
Insulin, µU/mL0.82 ± 0.340.86 ± 0.610.78 ± 0.400.92 ± 0.340.89 ± 0.53
Glucagon, pg/mL30.8 ± 4.830.4 ± 6.431.2 ± 10.829.7 ± 7.334.3 ± 12.5
QUICKI1.53 ± 0.791.83 ± 1.11.70 ± 0.861.29 ± 0.561.65 ± 1.01
NEFA, µg/L466 ± 98.7440 ± 121.3401 ± 55.4386 ± 110.9430 ± 59.3
Treatment groups; G1, fed choline-sufficient L-amino acid-defined (CSAA) diet; G2, fed choline-deficient L-amino acid-defined (CDAA) diet; G3, CDAA and canagliflozin (10 mg/kg/day); G4, CDAA and teneligliptin (0.3 mg/kg/day); G5, CDAA and canagliflozin(CA) (10 mg/kg/day)+teneligliptin (TE) (0.3 mg/kg/day). Data are represented as mean ± SD. Statistically significant as compared to G1 (‡ p < 0.01) and G2 († p < 0.01). Abbreviations: BW, body weight; ALT, alanine aminotransferase; ALB, albumin; T-Bil, total bilirubin; TG, triglyceride; QUICKI, quantitative insulin sensitivity check index; NEFA, nonesterified fatty acids.
Table
Table 2. Non-alcoholic fatty liver disease activity score in experimental groups in a non-diabetic rat model of steatohepatitis.
Table 2. Non-alcoholic fatty liver disease activity score in experimental groups in a non-diabetic rat model of steatohepatitis.
CSAACDAACDAA+CACDAA+TECDAA+CA+TE
(G1)(G2)(G3)(G4)(G5)
Steatosis02.8 ± 0.42.3 ± 0.5 †2.5 ± 0.51.9 ± 0.5 ‡
Ballooning01.7 ± 0.51.2 ± 0.4 †1.4 ± 0.51.2 ± 0.4 †
Inflammation02.4 ± 0.51.9 ± 0.3 †2.3 ± 0.51.6 ± 0.7 ‡
Treatment groups; G1, fed choline-sufficient L-amino acid-defined (CSAA) diet; G2, fed choline-deficient L-amino acid-defined (CDAA) diet; G3, CDAA and canagliflozin (10 mg/kg/day); G4, CDAA and teneligliptin (10mg/kg/day); G5, CDAA and canagliflozin(CA)(10 mg/kg/day)+teneligliptin (TE) (10 mg/kg/day). Data are represented as mean ± SD. † p < 0.05 compared to CDAA diet,G2. ‡ p < 0.01 compared to CDAA diet,G2.

Share and Cite

MDPI and ACS Style

Ozutsumi, T.; Namisaki, T.; Shimozato, N.; Kaji, K.; Tsuji, Y.; Kaya, D.; Fujinaga, Y.; Furukawa, M.; Nakanishi, K.; Sato, S.; et al. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. Int. J. Mol. Sci. 2020, 21, 2164. https://doi.org/10.3390/ijms21062164

AMA Style

Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, et al. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. International Journal of Molecular Sciences. 2020; 21(6):2164. https://doi.org/10.3390/ijms21062164

Chicago/Turabian Style

Ozutsumi, Takahiro, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Masanori Furukawa, Keisuke Nakanishi, Shinya Sato, and et al. 2020. "Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis" International Journal of Molecular Sciences 21, no. 6: 2164. https://doi.org/10.3390/ijms21062164

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop